TY - JOUR T1 - Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2021-001925 VL - 7 IS - 3 SP - e001925 AU - Jose María Álvaro Gracia AU - Carlos Sanchez-Piedra AU - Javier Manero AU - María Ester Ruiz-Lucea AU - Laura López-Vives AU - Cristina Bohorquez AU - Julia Martinez-Barrio AU - Gema Bonilla AU - Paloma Vela AU - María Jesús García-Villanueva AU - María Teresa Navío-Marco AU - Marina Pavía AU - María Galindo AU - Celia Erausquin AU - Miguel A Gonzalez-Gay AU - Inigo Rua-Figueroa AU - Jose M Pego-Reigosa AU - Isabel Castrejon AU - Jesús T Sanchez-Costa AU - Enrique González-Dávila AU - Federico Diaz-Gonzalez A2 - , Y1 - 2021/12/01 UR - http://rmdopen.bmj.com/content/7/3/e001925.abstract N2 - Objectives To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases.Methods The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed.Results A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients’ hospitalisation.Conclusions The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.Data are available on reasonable request. The data supporting the results of this study are the property of the Spanish Society of Rheumatology (SER), and are not publicly available. However, the data are released upon reasoned request and with the permission of the Spanish Society of Rheumatology. ER -